by Greg Williams
(Medical Xpress)—Changes to a gene called LZTR1 predispose people to develop a rare disorder where multiple tumors called schwannomas form near nerve pathways, according to a study published today in the journal Nature Genetics and led by researchers from the University of Alabama at Birmingham.
The formation of multiple schwannomas is one sign that a person has the genetic disorder called schwannomatosis, which is one of the three major forms of neurofibromatosis, besides neurofibromatosis types 1 and 2. The condition is so named because the tumors originate in Schwann cells that form a nerve sheath and insulate nerve pathways to cause severe, chronic pain in many patients.
To date, physicians cannot give most patients a confirmed diagnosis for schwannomatosis, even if they show symptoms, because changes in genes linked to the condition by past studies explain only about 50 percent of familial and less than 10 percent of sporadic cases.
Work in 2007 determined that inheritable mutations in SMARCB1 predisposed to schwannomatosis. In addition, the schwannomas showed a loss of the long arm of chromosome 22, and different mutations in the neurofibromatosis type 2 (NF2) gene were found in each tumor studied.
Despite these many known details, much of the risk for schwannomatosis remained unexplained going into the current study. Several research groups had proposed that other schwannomatosis-predisposing genes existed, but no one had found any.
Specializing in genetic studies for all forms of the neurofibromatoses, the UAB Medical Genomics Laboratory chose to focus its research on a subset of schwannomatosis samples that did not harbor SMARCB1 mutations, which framed their experiments such that the role of LZTR1 was revealed.
"We have been working urgently to identify the genetic mechanisms behind these diseases because doing so is central to efforts to understand schwannoma tumor development as well as to identify new drug treatments," said Ludwine Messiaen, Ph.D., director of the Medical Genomics Laboratory, professor in the Division of Clinical Genetics in the Department of Genetics within the UAB School of Medicine and corresponding study author. "This is pertinent as only some of the schwannomas can be surgically removed without neurological consequences, and there is no widely accepted approach for treating the severe, chronic pain in these patients."
The study, conceived and coordinated by Arkadiusz Piotrowski of the University of Gdansk in Poland and Messiaen, resulted in the identification of LZTR1 on chromosome 22q as a novel tumor-suppressor gene predisposing to multiple schwannomas in patients without a mutation in SMARCB1. The results were seen in patients whose schwannomas also showed a loss of the long arm of chromosome 22 and a different somatic NF2 mutation in each tumor.
The team found that in all 25 schwannomas studied from 16 unrelated schwannomatosis patients, all tumors showing a loss of the long arm of chromosome 22 and a different somatic NF2 mutation in each tumor also had LZTR1 mutations present, strongly supporting the contribution to the disease by the combination of these factors.
The LZTR1 mutations were found using massive parallel sequencing (e.g. "next-generation sequencing") of highly evolutionary conserved sequences specifically on chromosome 22. LZTR1 mutations likely will be found in a high fraction of familial as well as sporadic schwannomatosis patients, whose predisposition is not caused by SMARCB1, says Messiaen. Indeed, LZTR1 mutations were found in 6/6 familial and 8/11 sporadic such patients.
Both causal genes, LZTR1 and SMARCB1, show a potential functional link to chromatin remodeling mechanisms, which play a crucial role in cell differentiation and adaptation to environmental stimuli. Further, LZTR1 and SMARCB1 are known to interact with histone deacetylase 4 or HDAC4, which is a target for histone deacetylase inhibitors, a new class of anti-tumor drugs. The present findings will encourage further studies aiming at potential treatment for schwannomatosis.
The results published today will have broader implications, as LZTR1 was recently shown, in an independent study, to contribute to tumor development in a subset of patients with glioblastoma multiforme, the most aggressive type of brain tumor.
"Recent independent studies have shown that SMARCB1 and LZTR1 interact with histone deacetylase 4, and histone deacetylase inhibitors are emerging as a new class of anti-tumor drugs," said Bruce Korf, M.D., Ph.D., chair of the UAB Department of Genetics, a study co-author and principal investigator for The Neurofibromatosis Clinical Trials Consortium at UAB. "One of these drugs, called AR-42, was recently reported to inhibit growth in schwannoma and meningioma cells. This creates the prospect of further testing of the drug as a potential treatment for schwannomatosis."
Explore further: REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials
Medical Xpress on facebook
Related Stories
REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials
Dec 09, 2013
As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches—including outcome measures specific to NF—are needed. The first report from the Response Evaluation in ...
Study reveals genes that drive brain cancer
Aug 05, 2013
A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common—and ...
Study brings greater understanding of tumor growth mechanism
May 16, 2013
A study led by researchers from Plymouth University Peninsula Schools of Medicine and Dentistry has for the first time revealed how the loss of a particular tumour suppressing protein leads to the abnormal growth of tumours ...
Anti-angiogenesis treatment improves hearing in some NF2 patients
Jul 08, 2009
Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2). In a paper to appear in the July 23 New England Journal of Medicine, which ...
Gene sequencing project finds family of drugs with promise for treating childhood tumor
Dec 09, 2013
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle ...
Recommended for you
New genetic screening test for Lynch Syndrome
30 minutes ago
People at high risk of cancer of the bowel and womb due to a genetic condition will receive a more accurate diagnosis as a result of a new model developed by a team of international scientists.
Genetic screening identifies genes driving resistance with a guide RNA library
14 hours ago
Researchers have developed a method to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types.
Gene that influences the ability to remember faces found
17 hours ago
New findings suggest the oxytocin receptor, a gene known to influence mother-infant bonding and pair bonding in monogamous species, also plays a special role in the ability to remember faces. This research has important implications ...
Explainer: What is heritability?
23 hours ago
Schizophrenia, depression, bipolar disorder and autism have all had recent attention for being "genetically caused". ...
Genetics that protects your heart
23 hours ago
(Medical Xpress)—Researchers have found a key piece of the puzzle as to why an isolated population in Greece may live healthy lives. They have found that a genetic variant known to protect the heart is ...
Genetic profiling tracks progression from manageable blood cancer into deadly disease
23 hours ago
Genetic profiling has painted the clearest picture yet of how a type of blood cancer – follicular lymphoma – develops and changes from a manageable disease into an aggressive cancer, offering new targets ...
User comments
© Medical Xpress 2011-2013, Science X network
by Greg Williams
(Medical Xpress)—Changes to a gene called LZTR1 predispose people to develop a rare disorder where multiple tumors called schwannomas form near nerve pathways, according to a study published today in the journal Nature Genetics and led by researchers from the University of Alabama at Birmingham.
The formation of multiple schwannomas is one sign that a person has the genetic disorder called schwannomatosis, which is one of the three major forms of neurofibromatosis, besides neurofibromatosis types 1 and 2. The condition is so named because the tumors originate in Schwann cells that form a nerve sheath and insulate nerve pathways to cause severe, chronic pain in many patients.
To date, physicians cannot give most patients a confirmed diagnosis for schwannomatosis, even if they show symptoms, because changes in genes linked to the condition by past studies explain only about 50 percent of familial and less than 10 percent of sporadic cases.
Work in 2007 determined that inheritable mutations in SMARCB1 predisposed to schwannomatosis. In addition, the schwannomas showed a loss of the long arm of chromosome 22, and different mutations in the neurofibromatosis type 2 (NF2) gene were found in each tumor studied.
Despite these many known details, much of the risk for schwannomatosis remained unexplained going into the current study. Several research groups had proposed that other schwannomatosis-predisposing genes existed, but no one had found any.
Specializing in genetic studies for all forms of the neurofibromatoses, the UAB Medical Genomics Laboratory chose to focus its research on a subset of schwannomatosis samples that did not harbor SMARCB1 mutations, which framed their experiments such that the role of LZTR1 was revealed.
"We have been working urgently to identify the genetic mechanisms behind these diseases because doing so is central to efforts to understand schwannoma tumor development as well as to identify new drug treatments," said Ludwine Messiaen, Ph.D., director of the Medical Genomics Laboratory, professor in the Division of Clinical Genetics in the Department of Genetics within the UAB School of Medicine and corresponding study author. "This is pertinent as only some of the schwannomas can be surgically removed without neurological consequences, and there is no widely accepted approach for treating the severe, chronic pain in these patients."
The study, conceived and coordinated by Arkadiusz Piotrowski of the University of Gdansk in Poland and Messiaen, resulted in the identification of LZTR1 on chromosome 22q as a novel tumor-suppressor gene predisposing to multiple schwannomas in patients without a mutation in SMARCB1. The results were seen in patients whose schwannomas also showed a loss of the long arm of chromosome 22 and a different somatic NF2 mutation in each tumor.
The team found that in all 25 schwannomas studied from 16 unrelated schwannomatosis patients, all tumors showing a loss of the long arm of chromosome 22 and a different somatic NF2 mutation in each tumor also had LZTR1 mutations present, strongly supporting the contribution to the disease by the combination of these factors.
The LZTR1 mutations were found using massive parallel sequencing (e.g. "next-generation sequencing") of highly evolutionary conserved sequences specifically on chromosome 22. LZTR1 mutations likely will be found in a high fraction of familial as well as sporadic schwannomatosis patients, whose predisposition is not caused by SMARCB1, says Messiaen. Indeed, LZTR1 mutations were found in 6/6 familial and 8/11 sporadic such patients.
Both causal genes, LZTR1 and SMARCB1, show a potential functional link to chromatin remodeling mechanisms, which play a crucial role in cell differentiation and adaptation to environmental stimuli. Further, LZTR1 and SMARCB1 are known to interact with histone deacetylase 4 or HDAC4, which is a target for histone deacetylase inhibitors, a new class of anti-tumor drugs. The present findings will encourage further studies aiming at potential treatment for schwannomatosis.
The results published today will have broader implications, as LZTR1 was recently shown, in an independent study, to contribute to tumor development in a subset of patients with glioblastoma multiforme, the most aggressive type of brain tumor.
"Recent independent studies have shown that SMARCB1 and LZTR1 interact with histone deacetylase 4, and histone deacetylase inhibitors are emerging as a new class of anti-tumor drugs," said Bruce Korf, M.D., Ph.D., chair of the UAB Department of Genetics, a study co-author and principal investigator for The Neurofibromatosis Clinical Trials Consortium at UAB. "One of these drugs, called AR-42, was recently reported to inhibit growth in schwannoma and meningioma cells. This creates the prospect of further testing of the drug as a potential treatment for schwannomatosis."
Explore further: REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials
Medical Xpress on facebook
Related Stories
REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials
Dec 09, 2013
As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches—including outcome measures specific to NF—are needed. The first report from the Response Evaluation in ...
Study reveals genes that drive brain cancer
Aug 05, 2013
A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common—and ...
Study brings greater understanding of tumor growth mechanism
May 16, 2013
A study led by researchers from Plymouth University Peninsula Schools of Medicine and Dentistry has for the first time revealed how the loss of a particular tumour suppressing protein leads to the abnormal growth of tumours ...
Anti-angiogenesis treatment improves hearing in some NF2 patients
Jul 08, 2009
Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2). In a paper to appear in the July 23 New England Journal of Medicine, which ...
Gene sequencing project finds family of drugs with promise for treating childhood tumor
Dec 09, 2013
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle ...
Recommended for you
New genetic screening test for Lynch Syndrome
30 minutes ago
People at high risk of cancer of the bowel and womb due to a genetic condition will receive a more accurate diagnosis as a result of a new model developed by a team of international scientists.
Genetic screening identifies genes driving resistance with a guide RNA library
14 hours ago
Researchers have developed a method to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types.
Gene that influences the ability to remember faces found
17 hours ago
New findings suggest the oxytocin receptor, a gene known to influence mother-infant bonding and pair bonding in monogamous species, also plays a special role in the ability to remember faces. This research has important implications ...
Explainer: What is heritability?
23 hours ago
Schizophrenia, depression, bipolar disorder and autism have all had recent attention for being "genetically caused". ...
Genetics that protects your heart
23 hours ago
(Medical Xpress)—Researchers have found a key piece of the puzzle as to why an isolated population in Greece may live healthy lives. They have found that a genetic variant known to protect the heart is ...
Genetic profiling tracks progression from manageable blood cancer into deadly disease
23 hours ago
Genetic profiling has painted the clearest picture yet of how a type of blood cancer – follicular lymphoma – develops and changes from a manageable disease into an aggressive cancer, offering new targets ...
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment